Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan

PHARMACOGENOMICS · Published 2026-07-31 · DOI 10.1080/14622416.2026.2711877

Free full text

Authors (6)

Aftab Ullah, Abdur Rahim, Asif Jan, Muhammad Khan, Junaid Iqbal, Mequanente Dagnaw

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ullah, A., Rahim, A., Jan, A., et al. (2026). Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan. PHARMACOGENOMICS. https://doi.org/10.1080/14622416.2026.2711877

Related articles

• Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 · The Lancet · 2025 · Cites or is cited by this article
• How to implement pre-emptive pharmacogenetic testing in the acute hospital setting · PHARMACOGENOMICS · 2025 · Same journal
• Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe · PHARMACOGENOMICS · 2025 · Same journal
• ADIPOQ genotypes and haplotypes, circulating adiponectin levels and responsiveness to antihypertensive therapy in preeclampsia · PHARMACOGENOMICS · 2025 · Same journal
• UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients · PHARMACOGENOMICS · 2025 · Same journal
• Pharmacogenomic testing for Prader-Willi syndrome: a mixed methods analysis of caregiver experiences and utilization · PHARMACOGENOMICS · 2025 · Same journal
• Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes · PHARMACOGENOMICS · 2025 · Same journal
• Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis · PHARMACOGENOMICS · 2025 · Same journal
• Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine · PHARMACOGENOMICS · 2026 · Same journal
• Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use · PHARMACOGENOMICS · 2026 · Same journal